Peritoneal recurrence in gastric cancer after curative gastrectomy: risk factors and predictive score model

Author(s)

Szor, Daniel Jose ; Pereira, Marina Alessandra ; Ramos, Marcus Fernando Kodama Pertille ; Nigro, Bruna de Camargo ; Dias, Andre Roncon ; Ribeiro Jr, Ulysses

• Document type: Journal article
• Source: JOURNAL OF GASTROINTESTINAL SURGERY; v. 29, n. 1, p. 8-pg., 2025-01-06.

Abstract

Background: Peritoneal recurrence (PR) remains the most common pattern of relapse in gastric cancer (GC), even after curative resection. Given its dismal prognosis, the identification of risk factors for PR is essential for developing new treatment modalities and selecting a more appropriate subgroup of patients. This study aimed to evaluate the risk factors and survival outcomes of patients with GC who had PR and to develop a risk score to predict PR. Methods: All patients with GC who underwent curative gastrectomy were included. For analysis, patients were divided into no recurrence (NR), recurrence in other sites (ROS), and PR. Risk factors for PR were analyzed to build a risk score. Results: Among 622 patients with GC, 460 (74.0%) had NR, 98 (15.7%) had ROS, and 64 (10.3%) had PR. Female patients, linitis on computed tomography, depth of tumor invasion, and diffuse/mixed type were associated with PR. Patients with PR had worse overall survival than those with ROS (22.0 vs 29.8 months, respectively; P = .008). The median survival estimates after recurrence were 5.0 months in the PR group and 9.9 months in the ROS group (P < .001). The scoring system developed with 8 variables had an accuracy of 81% in predicting PR. Accordingly, 385 patients (61.9%) were classified as low risk, and 237 patients (38.1%) were classified as high risk. Among the 64 patients with PR, 53 (82.8%) were correctly classified as high risk (P < .001). Conclusion: Patients with PR had distinct clinicopathologic characteristics and extremely restricted survival compared with patients with recurrence in other sites. The risk-scoring model was able to identify patients at higher risk of PR. (c) 2024 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. (AU)

• FAPESP's process: 20/13249-0 - Evaluation of intraperitoneal chemotherapy in treatment of gastric cancer in patients with peritoneal carcinomatosis
• Grantee: André Roncon Dias
• Support Opportunities: Regular Research Grants